COMMUNIQUÉS West-GlobeNewswire

Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region
21/01/2026
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore Brain Logo ST. LOUIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Restore [...]
“Medical Travel Month” January 2026 Sponsored by Medical Travel & Digital Health News in SHSMD American Hospital Association’s Calendar of Health Observances
21/01/2026
OAKLAND, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Medical Travel & Digital Health News (MTDHN) , the leading bi-monthly online newsletter covering the business of medical travel and digital solutions worldwide, today [...]
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
21/01/2026
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company [...]
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
21/01/2026
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical [...]
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
21/01/2026
New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
Manhattan Wellness Joins Lumina Therapy Alliance, Expanding the Nation’s Premier In-Person Mental Health Network
21/01/2026
Led by visionary founder Jennifer Teplin, Manhattan Wellness strengthens Lumina’s footprint for New York’s business community and signals rapid national expansion. NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lumina [...]
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
21/01/2026
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in vision in 2024 KNOXVILLE, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
21/01/2026
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents [...]
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
21/01/2026
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional [...]
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
21/01/2026
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society [...]
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
21/01/2026
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19 th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral [...]
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
21/01/2026
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management [...]
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
21/01/2026
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the [...]
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
21/01/2026
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare Marketing CAMPBELL, Calif. and NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD). For nearly three decades, [...]
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
21/01/2026
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE [...]
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
21/01/2026
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
21/01/2026
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000 [...]
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
21/01/2026
Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, [...]

Pages